Article
Immunology
Mate Kiss, Els Lebegge, Aleksandar Murgaski, Helena Van Damme, Daliya Kancheva, Jan Brughmans, Isabelle Scheyltjens, Ali Talebi, Robin Maximilian Awad, Yvon Elkrim, Pauline M. R. Bardet, Sana M. Arnouk, Cleo Goyvaerts, Johan Swinnen, Frank Aboubakar Nana, Jo A. Van Ginderachter, Damya Laoui
Summary: This study found that cancer-associated inflammation can enhance the expression of JAM-A on circulating monocytes, but the function of JAM-A in tumor-infiltrating myeloid cells is little understood. Through gene knockout mouse experiments and RNA sequencing, we found that JAM-A is dispensable for the recruitment and transcriptional reprogramming of myeloid cells.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Cell Biology
Kamila Czubak-Prowizor, Anna Babinska, Maria Swiatkowska
Summary: F11R/JAM-A is a transmembrane glycoprotein of the immunoglobulin superfamily that plays a role in regulating various biological processes in cells. Its involvement in carcinogenesis and tissue-specific roles in cancer progression are still debated topics in research.
MOLECULAR AND CELLULAR BIOCHEMISTRY
(2022)
Article
Biochemistry & Molecular Biology
Priscilla E. Day-Walsh, Bryony Keeble, Gothai Pirabagar, Samuel J. Fountain, Paul A. Kroon
Summary: Junctional adhesion molecules (JAMs) play important roles in virus infection and inflammation. This study found that JAM-B is expressed in leukocytes and is regulated through multiple pathways, including the NF-kappa B pathway at the transcriptional level and the ubiquitin-proteosome pathway at the post-translational level.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Gastroenterology & Hepatology
Miguel S. Marques, Ana C. Costa, Hugo Osorio, Marta L. Pinto, Sandra Relvas, Mario Dinis-Ribeiro, Fatima Carneiro, Marina Leite, Ceu Figueiredo
Summary: Helicobacter pylori infects approximately half of the world's population and is a major risk factor for peptic ulcer disease and gastric cancer. It disrupts epithelial integrity by targeting the junctional adhesion molecule-A (JAM-A) and uses a unique strategy to do so. This study identified PqqE (HP1012) as the virulence factor responsible for cleaving JAM-A, providing new insights into the pathogenesis of this infection.
Article
Medicine, Research & Experimental
Qian Wu, Rui Li, Qing-Xiang Wang, Meng-Yu Zhang, Ting-Ting Liu, Yi-Qing Qu
Summary: Our study revealed the oncogenic role of JAML in LUAD, showing that elevated JAML expression is positively correlated with pT and pTNM. Silencing JAML significantly inhibited malignant behaviors of LUAD cells, induced cell cycle arrest at G(0)/G(1) phase, and promoted apoptosis, possibly through inactivation of the Wnt/beta-catenin pathway in LUAD cells. Rescue experiments confirmed the effects of JAML could be reversed by Wnt/beta-catenin pathway activator in A549 cells. This suggests that JAML may serve as a predictive biomarker and potential therapeutic target for LUAD.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Article
Oncology
Yvonne E. Smith, Guannan Wang, Ciara L. Flynn, Stephen F. Madden, Owen MacEneaney, Rodrigo G. B. Cruz, Cathy E. Richards, Hanne Jahns, Marian Brennan, Mattia Cremona, Bryan T. Hennessy, Katherine Sheehan, Alexander Casucci, Faizah A. Sani, Lance Hudson, Joanna Fay, Sri H. Vellanki, Siobhan O'Flaherty, Marc Devocelle, Arnold D. K. Hill, Kieran Brennan, Saraswati Sukumar, Ann M. Hopkins
Summary: Specific drug targets for breast ductal carcinoma in situ (DCIS) are difficult to determine, but this study suggests that JAM-A, a cell surface protein, could be a potential therapeutic target in DCIS patients. The study found that JAM-A is upregulated in DCIS patient tissues and a novel JAM-A-binding peptide inhibitor showed efficacy in inhibiting tumor growth in in vivo models. This finding provides valuable insights for the development of novel treatments for DCIS patients.
Article
Oncology
Yuying Fang, Jianmin Yang, Guohong Zu, Changsheng Cong, Shuai Liu, Fei Xue, Shuzhen Ma, Jie Liu, Yuping Sun, Meili Sun
Summary: JAML, a newly discovered junctional adhesion molecule, plays a critical role in promoting gastric cancer cell migration and proliferation, potentially serving as a novel diagnostic biomarker and therapeutic target for gastric cancer.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Andrea Lampis, Jens C. Hahne, Pierluigi Gasparini, Luciano Cascione, Somaieh Hedayat, Georgios Vlachogiannis, Claudio Murgia, Elisa Fontana, Joanne Edwards, Paul G. Horgan, Luigi Terracciano, Owen J. Sansom, Carlos D. Martins, Gabriela Kramer-Marek, Carlo M. Croce, Chiara Braconi, Matteo Fassan, Nicola Valeri
Summary: JAM-A downregulation is common in CRC and correlates with poor prognosis; Dysregulation of JAM-A promotes invasiveness and metastasis in CRC by activating multiple oncogenic pathways.
CELL DEATH AND DIFFERENTIATION
(2021)
Review
Neurosciences
Davide Comoletti, Laura Trobiani, Arnaud Chatonnet, Yves Bourne, Pascale Marchot
Summary: Cell adhesion involves the formation of protein complexes between two cells, with neural cell-adhesion proteins using cholinesterase-like domains to bind cognate partners. These proteins, including neuroligins, have unique structural features but share the ability to recognize and bind protein partners.
Article
Biology
Kamila Czubak-Prowizor, Maria Swiatkowska
Summary: JAM-A is a tight junction component that regulates various cellular processes. Its aberrant expression is associated with poor prognosis in gynecological cancers. However, its role in cancer is complex and tumor-type specific.
Article
Biochemistry & Molecular Biology
Christopher Mendoza, Dario Mizrachi
Summary: Decades of evidence suggest that alterations in cell adhesion properties contribute to the invasive and migratory phenotype of neoplastic cells. The role of tight junction proteins in the tumor microenvironment is crucial. Reprogramming immune cells using CAR-T cells to target and eliminate tumors has been approved as a therapy. Researchers have developed a new biologic that specifically targets cancer cells and reduces proliferation and metastasis.
Article
Integrative & Complementary Medicine
Qian Wu, Yong-bin Wang, Xiao-wen Che, Hui Wang, Wei Wang
Summary: JAML protein is an oncogenic protein in lung adenocarcinoma (LUAD) and may serve as a novel therapeutic target. The flavonoid kaempferol inhibits JAML, leading to suppression of proliferation, migration, and invasion of LUAD cells, and partially inhibits epithelial-mesenchymal transition (EMT) through the PI3K/AKT/mTOR pathway. These findings suggest that JAML is a new target for kaempferol in LUAD cells.
JOURNAL OF INTEGRATIVE MEDICINE-JIM
(2023)
Article
Biology
Sayaka Ishihara, Tsuyoshi Sato, Noriyuki Fujikado, Haruka Miyazaki, Takayuki Yoshimoto, Hiromitsu Yamamoto, Shinji Fukuda, Koko Katagiri
Summary: T-cell-specific Rap1 deletion leads to spontaneous colitis in mice by impairing the induction of intestinal RORγt(+) Treg cells. In the absence of Rap1, Th17 cells increase in a microbiota-dependent manner, and blocking IL-17A production prevents colitis development. Rap1 deficiency in T cells impairs the development or maintenance of Rorγt(+) Tregs in the colonic lamina propria, resulting in an increase in pathogenic Th17 cells and spontaneous colitis.
COMMUNICATIONS BIOLOGY
(2022)
Article
Cell Biology
Daniel Kummer, Tim Steinbacher, Sonja Tholmann, Mariel Flavia Schwietzer, Christian Hartmann, Simone Horenkamp, Sabrina Demuth, Swetha S. D. Peddibhotla, Frauke Brinkmann, Bjorn Kemper, Jurgen Schnekenburger, Matthias Brandt, Timo Betz, Ivan Liashkovich, Ivan U. Kouzel, Victor Shahin, Nathalie Corvaia, Klemens Rottner, Katsiaryna Tarbashevich, Erez Raz, Lilo Greune, M. Alexander Schmidt, Volker Gerke, Klaus Ebnet
Summary: This study identifies the cell adhesion molecule JAM-A as a central regulator of contact inhibition of locomotion (CIL) in tumor cells. JAM-A links to αvβ5 integrin through tetraspanins CD9 and CD81, and inhibits the activity of Src. Loss of JAM-A leads to increased motility, enhanced cell-matrix turnover, and failure to halt migration upon collision with other cells. Proper regulation of CIL also depends on αvβ5 integrin engagement.
JOURNAL OF CELL BIOLOGY
(2022)
Article
Oncology
Miki Yamaguchi, Sachie Hirai, Masashi Idogawa, Toshiyuki Sumi, Hiroaki Uchida, Naoki Fujitani, Motoko Takahashi, Yuji Sakuma
Summary: There is a need for novel and effective treatments for small cell lung carcinoma (SCLC). This study investigated the use of an antibody-drug conjugate (ADC) targeting junctional adhesion molecule 3 (JAM3) as a potential therapy for SCLC. The results showed that JAM3 mRNA was expressed at higher levels in SCLC cell lines and tissues compared to lung adenocarcinoma. The ADC specifically targeting JAM3 exhibited dose- and time-dependent antitumor effects on SCLC cells. Silencing JAM3 alone suppressed the growth of SCLC cells. These findings suggest that targeting JAM3 with an ADC could be a promising approach for treating SCLC.
EXPERIMENTAL CELL RESEARCH
(2023)
